Close menu




Health

Photo credits: pixabay.com

Commented by Fabian Lorenz on July 28th, 2026 | 07:05 CEST

Turnaround Stocks with Up to 200% Upside? Renk, Eckert & Ziegler and Power Metallic Mines in Focus

  • PGMs
  • Copper
  • Electrification
  • Defense
  • Healthcare

Renk's shares have fallen by around 50% since October 2025. Has this created an attractive entry opportunity? Jefferies certainly believes so, assigning the stock a fair value of EUR 60. The company's upcoming half-year results are expected to be strong, with analysts anticipating an improvement in second-quarter margins. The company has reported operational success in the US. Power Metallic Mines could be on the verge of a strong rally. Copper, one of the world's most sought-after metals, is a key component of the company's world-class polymetallic deposit in Canada. Analysts see nearly 200% upside potential, while several important catalysts are expected in the near future. Meanwhile, Eckert & Ziegler has been in a downtrend for the past year. The market entry of a new competitor has weighed on the shares, but analysts believe investors' concerns are overdone.

Read

Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST

Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?

  • Biotechnology
  • Healthcare
  • Innovations
  • Cancer
  • Pharma

Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.

Read

Commented by Stefan Feulner on April 10th, 2026 | 07:05 CEST

Strategy, Aspermont, Redcare Pharmacy – Turnaround Opportunities Back in Focus

  • bigdata
  • Digitization
  • crypto
  • Healthcare
  • ecommerce

Markets are increasingly pricing in comeback potential. While the largest cryptocurrency climbs back above USD 70,000 and institutional inflows provide a tailwind, some players are unwaveringly betting on expansion despite billions in losses. At the same time, a data-driven platform model in the commodities sector is gaining traction, with over 180% upside potential, driven by scalable revenues and growing demand. In the e-commerce healthcare market, too, an operational turnaround following a prolonged period of weakness is triggering double-digit price movements. The combination of turnaround dynamics, oversold valuations, and long-term growth drivers could set the stage for further upside.

Read

Commented by Carsten Mainitz on February 12th, 2026 | 07:55 CET

Watch out! Gerresheimer slumps 30%, NEO Battery Materials as a game changer, Schott Pharma surprises positively

  • Batteries
  • BatteryMetals
  • packaging
  • manufacturing
  • Healthcare

Many stories of success and failure are written on the stock market. NEO Battery Materials, the game changer in battery technology, is particularly exciting. The Canadian company offers manufacturers of drones, robots, and electric vehicles customizable high-performance batteries produced in the West. With its innovative approach, the company is setting new standards in terms of performance, charging speed, and price, thereby addressing a huge market that experts estimate will grow to around USD 30 billion by 2032. The examples of Gerresheimer and Schott Pharma show how differently companies in the same industry can develop: Schott exceeded market expectations in the first quarter, while Gerresheimer shocked the markets once again.

Read

Commented by Armin Schulz on January 8th, 2026 | 07:05 CET

How to benefit from the healthcare industry's comeback in 2026: Novo Nordisk, Vidac Pharma, and Pfizer in focus

  • Biotechnology
  • Biotech
  • Pharma
  • Healthcare

After a disappointing year for investors in the pharmaceutical and biotech industries, the tide is now turning decisively on the stock market for these stocks. Political clarity, a return to major acquisitions, and groundbreaking clinical data are laying the foundation for a sustainable comeback. This new optimism is opening up concrete opportunities for strategic investments. Three companies exemplify these promising drivers: Novo Nordisk, Vidac Pharma, and Pfizer.

Read

Commented by Armin Schulz on December 2nd, 2025 | 07:00 CET

The demographic clock is ticking: How Bayer, Vidac Pharma, and Novo Nordisk are positioning themselves in the billion-dollar battle for our health

  • Biotechnology
  • Biotech
  • Pharma
  • Healthcare

The demographic clock is ticking inexorably. An aging society brings with it a flood of widespread diseases such as heart disease, cancer, and diabetes. Each one is a billion-dollar market that is pushing healthcare systems to their limits. As costs explode, brutal, cut-throat competition is emerging. The winner will not be the one with the most pills, but the one with the most effective solutions to the greatest medical and economic challenges of our time. Today, we take a look at how Bayer, Vidac Pharma, and Novo Nordisk plan to shape the future.

Read

Commented by André Will-Laudien on November 4th, 2025 | 07:30 CET

Amazing! Rollercoaster ride with Beyond Meat, recovery at Novo Nordisk and Eli Lilly, big returns with PanGenomic Health

  • Health
  • Vegan
  • healthtech
  • Sustainability
  • Food
  • Biotechnology
  • Pharma

Volatility in the growth stock sector has caused quite a few swings in recent weeks. While Novo Nordisk and Eli Lilly are still struggling with margin declines from semaglutide injections, shares of the plant-based meat provider Beyond Meat have been bouncing around like a ball in orbit. After a rapid tenfold increase in October, November appears to be all about the reverse gear, with the stock currently down 80% from its peak. Those with strong nerves and a quick hand on the mouse are in luck. Things are calmer and steadier with PanGenomic Health. Here, the high levels since summer must first be digested before the next upward cycle can begin. We highlight a few opportunities.

Read

Commented by Nico Popp on November 3rd, 2025 | 07:20 CET

Food innovations that spark the imagination: Planethic Group, Danone, Kerry Group

  • Food
  • foodtech
  • Sustainability
  • Vegan
  • Health

People will always eat and drink - or will they? This old saying is only partially true today. More and more people are paying close attention to what they eat. Instead of letting brand recognition or price dictate their choices when shopping, consumers have been embracing the trend of mindful eating for years, paying particular attention to healthy nutrition and their own well-being. In addition, food has become a way for individuals to express their identity and stand out from others. Ultimately, this is creating a fragmented market catering to diverse interests, which also offers significant opportunities for investors.

Read

Commented by Nico Popp on October 31st, 2025 | 07:00 CET

Health as a billion-dollar market: PanGenomic Health, Hims & Hers, WW International

  • Health
  • Healthcare
  • plantbased
  • Digitization
  • healthtech
  • Vegan

More and more people are taking a proactive approach to their health, with prevention and self-care trending. According to recent studies by McKinsey, the global wellness industry is now valued at around USD 2 trillion. Younger generations in particular are integrating health firmly into their lifestyles: nearly 30% of millennials and Gen Z in the US report that they are doing significantly more for their well-being today than they were a year ago. Instead of only taking action when they fall ill, many are focusing on prevention, digital health tools, and online communities for support and exchange. We take a look at the latest trends, revisit familiar names, and highlight an emerging startup that could also deliver healthy returns for your portfolio.

Read

Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST

Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves

  • Healthcare
  • Biotechnology
  • healthtech
  • Pharma
  • Innovations

The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.

Read